{"id":9267,"date":"2026-10-28T16:10:55","date_gmt":"2026-10-28T10:40:55","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/pplpharma-share-price-today-2026-10-28\/"},"modified":"2026-10-28T16:10:58","modified_gmt":"2026-10-28T10:40:58","slug":"pplpharma-share-price-today-2026-10-28","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/pplpharma-share-price-today-2026-10-28\/","title":{"rendered":"Piramal Pharma Share Price Today: Rises 18.36% in 2 Trading Sessions | 28 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: PPLPHARMA<\/strong> \u00b7 28 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b9231.00<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+16.24%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b9235.38 \/ \u20b9209.04<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b9198.72<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>11.62 crore<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>28 October 2026 \u00b7 03:25 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Piramal Pharma has risen 18.36% over 2 trading sessions; today&#x27;s move is +16.24%.<\/li>\n<li>Piramal Pharma reported its financial results for the quarter and half year ended September 30, 2026, showing consolidated revenue of \u20b92,617 crores for Q2 FY27, up 28% year-on-year. EBITDA for the quarter rose 72% year-on-year to \u20b9385 crores with margins expanding over 350 basis points to 14.7%. Buoyed by strong first-half momentum, management upgraded its FY27 revenue growth outlook to 19% to 20% with higher profitability.<\/li>\n<li>Trading volume was 50.00 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Piramal Pharma share price: 18.36% rise over 2 trading sessions<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Piramal Pharma Ltd. (PPLPHARMA) shares surged sharply today, trading up 16.24% at \u20b9231.00 compared to their previous close of \u20b9198.72. The stock opened at \u20b9214.10 and climbed to a day&#x27;s high of \u20b9235.38 while touching a low of \u20b9209.04.<\/p>\n<p class=\"wt-copy\">The broader market exhibited mild weakness, with the Nifty falling 0.22%, while the thematic Nifty Pharma sector index advanced 1.04%. Against this backdrop, Piramal Pharma outperformed both the benchmark index and its sector peers, building on a robust 5-day return of 20.82% and a 20-day return of 11.82%.<\/p>\n<p class=\"wt-copy\">The strong price action coincides with the release of the company&#x27;s financial results for the second quarter and half year ended September 30, 2026, announced on October 27, 2026. Management reported a 28% year-on-year rise in consolidated revenue from operations to \u20b92,617 crores for Q2 FY27 and a 72% jump in EBITDA to \u20b9385 crores, supported by robust performance across its CDMO, Complex Hospital Generics, and Consumer Healthcare businesses alongside an upgrade to its full-year FY27 guidance.<\/p>\n<p class=\"wt-copy\">11.62 crore shares traded by 28 October 2026 \u00b7 03:25 PM IST. This compares with a 20-day average daily volume of 23.24 lakh shares (50.00 times). The five-day average daily volume was 25.62 lakh shares. Separately, the NSE report for 27 October 2026 showed 12.72 lakh shares delivered, representing 44.25% of that day\u2019s traded volume. The same report recorded 40,081 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Strong financial results and FY27 guidance upgrade<\/strong><\/p>\n<p class=\"wt-copy\">The sharp rally in Piramal Pharma shares is directly supported by the release of Q2 FY27 financial results showing a 28% increase in operational revenue, a 72% surge in EBITDA, and an upgraded full-year outlook.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Q2 and H1 FY27 Financial Results and Guidance Upgrade<\/div>\n<div class=\"wt-card-date\">27 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Piramal Pharma reported its financial results for the quarter and half year ended September 30, 2026, showing consolidated revenue of \u20b92,617 crores for Q2 FY27, up 28% year-on-year. EBITDA for the quarter rose 72% year-on-year to \u20b9385 crores with margins expanding over 350 basis points to 14.7%. Buoyed by strong first-half momentum, management upgraded its FY27 revenue growth outlook to 19% to 20% with higher profitability.<\/p>\n<p class=\"wt-copy\">The earnings beat and guidance upgrade provide fundamental backing for investor sentiment and valuation re-rating.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Expiry of Commercial Arrangement with Bayer<\/div>\n<div class=\"wt-card-date\">1 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company announced that its sales and distribution support commercial arrangement with Bayer Pharmaceuticals Private Limited will conclude upon its natural expiry on December 31, 2026, and will not be renewed. Piramal Pharma noted that the arrangement accounts for less than 5% of consolidated revenue and expects no material impact on profitability or financial position.<\/p>\n<p class=\"wt-copy\">Clarifies the upcoming transition of a minor distribution contract without posing material earnings risks.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/PIRAMALPHARMA_30092026201259_SEIntimationAppointmentofCTO.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Clarification on Ontario Facility Funding News<\/div>\n<div class=\"wt-card-date\">1 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">In response to an exchange clarification request regarding a media report about a $1.7 million investment from the Government of Ontario for its Aurora facility, the company confirmed the funding support under the LSSUF program. It clarified that the grant aims to support infrastructure upgrades and operational efficiency, though it does not constitute a material event under listing regulations.<\/p>\n<p class=\"wt-copy\">Resolves exchange queries regarding regional operational grants without altering near-term financial expectations.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/PIRAMALPHARMA_30092026201259_SEIntimationAppointmentofCTO.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Press Release<\/div>\n<div class=\"wt-card-date\">28 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 27, 2026, titled &quot;Piramal Pharma Limited Announces Results for Q2 and H1 FY2&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Priyankamehta_27102026210401_PRandIRIntimation27Oct26sd.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Outcome of Board Meeting<\/div>\n<div class=\"wt-card-date\">28 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Priyankamehta_27102026210048_Outcome_of_BM_271026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">34.80%<\/div>\n<div class=\"wt-note\">34.80% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">13.65%<\/div>\n<div class=\"wt-note\">12.52% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">28.09%<\/div>\n<div class=\"wt-note\">27.09% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742857_21102026032628_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 12.71% on 30 September 2026. This compares with 13.18% on 30 June 2026, a change of -0.47 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 27 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">7.52 crore shares \u00b7 5.65%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Nippon Life India Trustee Ltd-A\/C Nippon India Small Cap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.08 crore shares \u00b7 1.56%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742857_21102026032628_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution of order inflows and capacity utilization across the CDMO business segments<\/li>\n<li>Integration progress and revenue contribution of the Kenalog product acquisition<\/li>\n<li>Transition management and business continuity following the impending expiry of the Bayer distribution agreement<\/li>\n<li>Sustained delivery volumes and liquidity levels relative to the 20-day average volume<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/pplpharma\/\">More Piramal Pharma news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Piramal Pharma company news?<\/h3>\n<p class=\"wt-copy\">Piramal Pharma reported its financial results for the quarter and half year ended September 30, 2026, showing consolidated revenue of \u20b92,617 crores for Q2 FY27, up 28% year-on-year. EBITDA for the quarter rose 72% year-on-year to \u20b9385 crores with margins expanding over 350 basis points to 14.7%. Buoyed by strong first-half momentum, management upgraded its FY27 revenue growth outlook to 19% to 20% with higher profitability.<\/p>\n<h3>How strong was Piramal Pharma\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">11.62 crore shares traded, 50.00 times the 20-day average daily volume. The price and volume data are dated 28 October 2026 \u00b7 03:25 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/pplpharma-share-price-today-2026-10-28\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/pplpharma-share-price-today-2026-10-28\/\"}, \"headline\": \"Piramal Pharma Share Price Today: Rises 18.36% in 2 Trading Sessions | 28 October 2026\", \"description\": \"Piramal Pharma has risen 18.36% over 2 trading sessions. Today it is 16.24% higher at \u20b9231.00. See price context, volume and key company developments.\", \"datePublished\": \"2026-10-28T16:09:20.296624+05:30\", \"dateModified\": \"2026-10-28T16:09:20.296624+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Piramal Pharma\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"PPLPHARMA\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/pplpharma-company-news-2026-10-28.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Press Release\",\"summary\":\"a press release dated October 27, 2026, titled \\\"Piramal Pharma Limited Announces Results for Q2 and H1 FY2\\\".\",\"source\":\"NSE\",\"published\":\"27-Oct-2026 21:04:21\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Priyankamehta_27102026210401_PRandIRIntimation27Oct26sd.pdf\"},{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"source\":\"NSE\",\"published\":\"27-Oct-2026 21:02:02\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Priyankamehta_27102026210048_Outcome_of_BM_271026.pdf\"},{\"title\":\"Piramal Pharma soars 15% in weak market on huge volume post Q2 results - Business Standard\",\"summary\":\"Piramal Pharma soars 15% in weak market on huge volume post Q2 results Business Standard\",\"source\":\"Business Standard\",\"published\":\"Wed, 28 Oct 2026 05:22:32 GMT\",\"source_type\":\"business media\",\"generic_watchlist\":false},{\"title\":\"Buzzing Stocks: L&T gains 5% on 33% jump in Q2 profit; Piramal Pharma surges 12% as it turns... - Moneycontrol.com\",\"summary\":\"Buzzing Stocks: L&T gains 5% on 33% jump in Q2 profit; Piramal Pharma surges 12% as it turns... Moneycontrol.com\",\"source\":\"Moneycontrol.com\",\"published\":\"Wed, 28 Oct 2026 04:16:46 GMT\",\"source_type\":\"business media\",\"generic_watchlist\":false}],\"recent_news\":[{\"summary\":\"a press release dated October 27, 2026, titled \\\"Piramal Pharma Limited Announces Results for Q2 and H1 FY2\\\".\",\"category\":\"Press Release\",\"date\":\"27-Oct-2026 21:04:21\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Priyankamehta_27102026210401_PRandIRIntimation27Oct26sd.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"27-Oct-2026 21:02:02\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Priyankamehta_27102026210048_Outcome_of_BM_271026.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"The exchange sought clarification from the company regarding a recent media report. Such a request is a verification step and does not by itself confirm the reported issue.\",\"category\":\"News Verification\",\"date\":\"01-Oct-2026 19:14:49\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/PIRAMALPHARMA_01102026105231_Responseletter.pdf\",\"headline\":\"Exchange clarification on media report\",\"impact\":\"This can influence near-term sentiment while investors wait for the company's response, but it becomes materially important only if the company confirms a financial or operational impact.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"'Exercise of call option for acquisition of additional equity stake in Yapan Bio PrivateLimited'.\",\"category\":\"Updates\",\"date\":\"10-Aug-2026 18:09:03\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Priyankamehta_10082026180821_SE_Disclosure_Call_option_exercise_-_Yapan.pdf\",\"headline\":\"Investment \/ acquisition update\",\"impact\":\"The transaction can affect growth strategy, capital allocation or market access. Investors should consider the size of the investment, ownership acquired and expected returns.\",\"importance_score\":4,\"completeness_score\":3}],\"promoter_pledge\":{\"summary\":\"The promoter\/promoter-group disclosure states that the shares covered by the filing were free from encumbrance.\",\"events\":[{\"summary\":\"Ajay G. Piramal Date: 6th April, 2026 To, To, BSE Limited National Stock Exchange of India Limited Mumbai Mumbai BSE Script code: 543635 NSE Symbol: PPLPHARMA Re.: Piramal Pharma Limited Sub: Declaration under Regulation 31(4) of SEBI (SAST) Regulations, 2011 from the Promoter Pursuant to the Regulation 31(4) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (\u201cSEBI SAST\u201d), we hereby declare that the Promoters or the Promoter Group have not made any encumbrance, directly or indirectly, on the shares \/ securities of the Company \u2018Piramal Pharma Limited\u2019 during the financial year 2025- 2026. You are requested to take note of the above. Thanking you, Yours faithfully For and on behalf of Promoter and Promoter Group Ajay G. Piramal\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"29-Jun-2026 19:45:27\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_sandeshc_11052026115720_39.pdf\",\"detail_level\":\"pdf_facts\"}],\"source\":\"NSE corporate filing\"},\"shareholding_snapshot\":{\"promoter_pct\":34.8,\"public_pct\":64.8,\"fii_pct\":13.65,\"dii_pct\":14.44,\"mf_pct\":12.71,\"institutional_pct\":28.09,\"noninst_pct\":36.71,\"mf_scheme_count\":27,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund\",\"shares\":75248994,\"pct\":5.65},{\"name\":\"Nippon Life India Trustee Ltd-A\/C Nippon India Small Cap Fund\",\"shares\":20758801,\"pct\":1.56}],\"period\":\"30-SEP-2026\",\"submission_date\":\"21-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742857_21102026032628_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":34.8,\"previous_fii_pct\":12.52,\"previous_dii_pct\":14.57,\"previous_mf_pct\":13.18,\"previous_institutional_pct\":27.09,\"previous_mf_scheme_count\":25,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null}} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Piramal Pharma has risen 18.36% over 2 trading sessions. Today it is 16.24% higher at \u20b9231.00. See price context, volume and key company developments.<\/p>\n","protected":false},"author":1,"featured_media":9266,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Piramal Pharma Share Price Today: Rises 18.36% in 2 Trading Sessions | 28 October 2026","_witty_meta_description":"Piramal Pharma has risen 18.36% over 2 trading sessions. Today it is 16.24% higher at \u20b9231.00. See price context, volume and key company developments.","_witty_primary_phrase":"Piramal Pharma share price today","_witty_reason_label":"Strong financial results and FY27 guidance upgrade","_witty_reason_confidence":"high","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[322],"class_list":["post-9267","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-pplpharma"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=9267"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9267\/revisions"}],"predecessor-version":[{"id":9268,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9267\/revisions\/9268"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/9266"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=9267"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=9267"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=9267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}